KAT6A and breast cancer: In KAT6A‐amplified ER+/HER2− breast cancer cell lines, including ZR‐75‐1 and CAMA‐1, ISM5043 demonstrated dose‐dependent antitumor efficacy as monotherapy, which correlated with the suppression of H3K23Ac and ERα protein levels.